![]() Please see the accompanying Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) Fact Sheet for Healthcare Providers Administering Vaccine for more information. In addition, you can report side effects to ModernaTX, Inc. Reports should include the words “Moderna COVID-19 Vaccine, Bivalent EUA” in the description section of the report. For further assistance with reporting to VAERS, call 1-80. Discard vial after 2 doses have been removed. Serious adverse events (irrespective of attribution to vaccination)Ĭases of Multisystem Inflammatory Syndrome (MIS)Ĭases of COVID-19 that result in hospitalization or deathĬomplete and submit reports to VAERS online at. Moderna COVID-19 Vaccines FDA Vial cap colorPink capped vials with yellow-bordered BIVALENT label BIVALENT Dark blue capped vial with gray-bordered label Supplied in multidose vial 2 doses per vialDo not confuse these with single-dose vials. ![]() Vaccine administration errors whether or not associated with an adverse event The vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS): ![]() Reporting Adverse Events and Vaccine Administration Errors Some vaccines require two shots for you to get the best protection and to fight off the virus. Limitations of Vaccine Effectiveness: The Moderna COVID-19 Vaccine, Bivalent may not protect all vaccine recipients.Ħ months through 36 months of age: Injection site erythema, pain and swelling axillary (or groin) swelling/tenderness, fever, irritability/crying, loss of appetite and sleepinessģ7 months of age and older: Injection site erythema, pain and swelling arthralgia, axillary (or groin) swelling/tenderness, chills, fatigue, fever, headache, myalgia, nausea/vomiting, and rash Procedures should be in place to avoid injury from fainting.Īltered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to Moderna COVID-19 Vaccine, Bivalent. Syncope (fainting): May occur in association with administration of injectable vaccines. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis ( ). The observed risk is highest in males 18 through 24 years of age. Myocarditis and Pericarditis: Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. Monitor vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines ( ). Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the vaccine. Staying up to date with all doses as soon as you are eligible is your best protection against serious illness and death from COVID-19.Do not administer the vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine or Moderna COVID-19 Vaccine, Bivalent. These vaccines are currently being distributed in Washington state. Several vaccines are authorized for emergency use or fully approved by the U.S. COVID-19 vaccination is one of the most important tools to end the COVID-19 pandemic. For vaccine-specific information, choose the vaccine tab. Will I be charged for the vaccine? Resources and Recommendationsįind additional resources and recommendations. The Washington State Department of Health is currently reviewing and updating our webpages and supporting resources to reflect these new recommendations. MRNA vaccines are preferred, but the Novavax COVID-19 vaccine is still available if you aren’t able or willing to get another vaccine. ![]() For young children, multiple doses continue to be recommended and will vary by age, vaccine, and which vaccines were previously received.Individuals ages 6 years and older who have already received an updated mRNA vaccine do not need to take any action unless they are 65 years or older or immunocompromised.CDC recommends that everyone ages 6 years and older receive an updated (bivalent) mRNA COVID-19 vaccine, regardless of whether they previously completed their (monovalent) primary series.Monovalent (original) mRNA COVID-19 vaccines will no longer be recommended for use in the United States.This allows more flexibility for healthcare providers to administer additional doses to immunocompromised patients as needed. CDC’s new recommendations allow an additional updated (bivalent) vaccine dose for adults ages 65 years and older and additional doses for people who are immunocompromised.The COVID-19 vaccine is available to people 6 months of age and older.Īpril 19th, 2023 – Following FDA regulatory action, CDC has taken steps to simplify COVID-19 vaccine recommendations and allow more flexibility for people at higher risk who want the option of added protection from additional COVID-19 vaccine doses.
0 Comments
Leave a Reply. |